341 related articles for article (PubMed ID: 20822152)
1. Physiological parameters for oral delivery and in vitro testing.
Mudie DM; Amidon GL; Amidon GE
Mol Pharm; 2010 Oct; 7(5):1388-405. PubMed ID: 20822152
[TBL] [Abstract][Full Text] [Related]
2. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
[TBL] [Abstract][Full Text] [Related]
3. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
[TBL] [Abstract][Full Text] [Related]
4. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based In vitro Models to Predict the Oral Dissolution and Absorption of a Solid Drug Delivery System.
Li Z; He X
Curr Drug Metab; 2015; 16(9):777-806. PubMed ID: 26264200
[TBL] [Abstract][Full Text] [Related]
6. Dynamic dissolution: a step closer to predictive dissolution testing?
McAllister M
Mol Pharm; 2010 Oct; 7(5):1374-87. PubMed ID: 20698545
[TBL] [Abstract][Full Text] [Related]
7. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
[TBL] [Abstract][Full Text] [Related]
8. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
9. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
10. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
11. In vitro dissolution absorption system (IDAS2): Use for the prediction of food viscosity effects on drug dissolution and absorption from oral solid dosage forms.
Silchenko S; Nessah N; Li J; Li LB; Huang Y; Owen AJ; Hidalgo IJ
Eur J Pharm Sci; 2020 Feb; 143():105164. PubMed ID: 31760121
[TBL] [Abstract][Full Text] [Related]
12. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
Fang JB; Robertson VK; Rawat A; Flick T; Tang ZJ; Cauchon NS; McElvain JS
Mol Pharm; 2010 Oct; 7(5):1466-77. PubMed ID: 20701327
[TBL] [Abstract][Full Text] [Related]
13. Dissolution testing of oral modified-release dosage forms.
Garbacz G; Klein S
J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
[TBL] [Abstract][Full Text] [Related]
14. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
15. [Biopharmaceutical considerations of dissolution testing used as a prognostic tool for oral drug adsorption].
Antal I
Acta Pharm Hung; 2001 Oct; 71(3):280-8. PubMed ID: 11961894
[TBL] [Abstract][Full Text] [Related]
16. In-Vitro Drug Dissolution Studies in Medicinal Compounds.
Bozal-Palabiyik B; Uslu B; Ozkan Y; Ozkan SA
Curr Med Chem; 2018; 25(33):4020-4036. PubMed ID: 29577852
[TBL] [Abstract][Full Text] [Related]
17. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
19. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
20. Simulating the postprandial stomach: physiological considerations for dissolution and release testing.
Koziolek M; Garbacz G; Neumann M; Weitschies W
Mol Pharm; 2013 May; 10(5):1610-22. PubMed ID: 23506381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
